The estimated Net Worth of David Colleran is at least $1.86 Millón dollars as of 11 March 2024. Mr Colleran owns over 16,809 units of Anika Therapeutics stock worth over $854,691 and over the last 9 years he sold ANIK stock worth over $427,405. In addition, he makes $579,215 as Exec. VP y Gen. Counsel & Corp. Sec. at Anika Therapeutics.
Mr has made over 15 trades of the Anika Therapeutics stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 16,809 units of ANIK stock worth $407,618 on 11 March 2024.
The largest trade he's ever made was exercising 20,975 units of Anika Therapeutics stock on 1 March 2019 worth over $745,452. On average, Mr trades about 3,337 units every 76 days since 2016. As of 11 March 2024 he still owns at least 35,245 units of Anika Therapeutics stock.
You can see the complete history of Mr Colleran stock trades at the bottom of the page.
David Colleran is the Exec. VP, Gen. Counsel & Corp. Sec. at Anika Therapeutics.
As the Exec. VP y Gen. Counsel & Corp. Sec. of Anika Therapeutics, the total compensation of Mr Colleran at Anika Therapeutics is $579,215. There are 3 executives at Anika Therapeutics getting paid more, with James Loerop having the highest compensation of $1,479,630.
Mr Colleran is 49, he's been the Exec. VP y Gen. Counsel & Corp. Sec. of Anika Therapeutics since . There are 14 older and 3 younger executives at Anika Therapeutics. The oldest executive at Anika Therapeutics Inc. is Joseph Bower, 81, who is the Independent Chairman of the Board.
Over the last 21 years, insiders at Anika Therapeutics have traded over $58,649,775 worth of Anika Therapeutics stock and bought 34,227 units worth $758,329 . The most active insiders traders include Charles H Sherwood, Farmaceutici S.P.A. Fidia y Joseph H Capper. On average, Anika Therapeutics executives and independent directors trade stock every 47 days with the average trade being worth of $613,258. The most recent stock trade was executed by Cheryl R Blanchard on 11 March 2024, trading 64,480 units of ANIK stock currently worth $1,563,640.
who we are we are anika therapeutics, a global medical technology company at the forefront of pain management, tissue regeneration and wound healing. we are committed to delivering innovative medical solutions that help patients feel better faster, look and feel younger and remain active. with over 7 million procedures performed over the past twenty years utilizing our proprietary technology, anika is helping individuals all over the world return to life naturally. our guiding principles we are innovators and creators. we value strong discipline and exceptional focus from our personnel, and we employ lean principles and agile processes in managing our business. this foundation of guiding values, combined with our entrepreneurial spirit, gives anika the ability and fortitude to generate innovative ideas and to grow our portfolio of successful products. what we do anika offers a broad spectrum of therapeutic treatments ranging from pain management and tissue regeneration to wound care an
Anika Therapeutics executives and other stock owners filed with the SEC include: